Drug Profile
Tezosentan
Alternative Names: ACT-050089; RO 610612Latest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Roche
- Developer Actelion Pharmaceuticals
- Class Heart failure therapies; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute heart failure; Cardiovascular disorders; Hepatorenal syndrome; Hypertension; Liver cirrhosis; Pulmonary arterial hypertension; Reperfusion injury
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 30 Apr 2013 Discontinued - Phase-II for Pulmonary arterial hypertension in France (IV)
- 30 Apr 2013 Discontinued - Phase-II for Pulmonary arterial hypertension in Japan (IV)